Our Purpose
Restoring Healthy Heart Physiology
We are focused on disrupting heart valve disease and restoring healthy heart function. Our team focuses on tackling clinical gaps and redefining positive outcomes by developing cutting-edge solutions designed to mimic the heart's native physiology.
Our Story
We started with tissue...
...and charted a path to TAVR
Our story began 40 years ago, after physicians realized that commercially available animal-based tissues were calcifying.1 Through decades of experimental surgical research, physicians and scientists developed a patented anti-calcification tissue that has been clinically proven to be calcium-free for up to 10 years2 and has been distributed for use in over 55,000 patients worldwide as a cardiac and vascular patch.3 Today, ADAPT® tissue is a key feature in the performance of the DurAVR® Transcatheter Heart Valve (THV) for aortic stenosis.
Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function.
We sought to restore healthy blood flow patterns by creating a new class of TAVR, a biomimetic valve. We believe that this valve will help restore healthy heart function so all patients can live their lives to the fullest.
Our story
We started with tissue...
Our story began 40 years ago, after physicians realized that commercially available animal-based tissues were calcifying.1 Through decades of experimental surgical research, physicians and scientists developed a patented anti-calcification tissue that has been clinically proven to be calcium-free for up to 10 years2 and has been distributed for use in over 55,000 patients worldwide as a cardiac and vascular patch.3 Today, ADAPT® tissue is a key feature in the performance of the DurAVR® Transcatheter Heart Valve (THV) for aortic stenosis.
...and charted a path to TAVR
Transcatheter Aortic Valve Replacement (TAVR) technologies were originally designed for older, high-risk patients. Today, younger, more active patients need a better solution that will not just open and close but restore healthy heart function.
We sought to restore healthy blood flow patterns by creating a new class of TAVR, a biomimetic valve. We believe that this valve will help restore healthy heart function so all patients can live their lives to the fullest.
Our AORTIC Values
Six words unite and inspire our team to redefine expectations and advance the field forward.
Accountability
We take responsibility for our actions and commitments, maintaining excellence through ongoing skill and knowledge development.
Objectivity
We hypothesize, develop, and test concepts, allowing us to make fair decisions using factual data and information.
Respect
We enjoy a positive, global culture by being thoughtful and considering the impact our decisions and behaviors have on others.
Teamwork
We work collaboratively by sharing ideas and building relationships with other employees and world-renowned physicians.
Integrity
We act ethically and are diligent in everything we do to inspire confidence and trust and maintain high quality standards.
Courage
We approach our work with imagination and perseverance and aren’t afraid to grow and try new things to achieve excellence.
We’re Hiring!
If you are driven by the opportunity to work on solutions that solve a critical unmet need, we want you on our team! Be part of something extraordinary and help change the future of cardiac care.
Leadership Team
Our experienced global leadership team brings together industry leaders in healthcare and business strategy.
Our Offices
Anteris' Principal Executive Offices are located in Brisbane, Australia with operations in the United States, Geneva and Perth.
References
- Fram C. New heart patch Aussie’s life work. The Sydney Morning Herald. 2013. https://www.smh.com.au/national/new-heart-patch-aussies-life-work-20130909-2tf95.html
- Neethling W, Rea A, Forster G, Bhirangi K. Performance of the ADAPT-Treated CardioCel® Scaffold in Pediatric Patients With Congenital Cardiac Anomalies: Medium to Long-Term Outcomes, Front Pediatr, 2020;8:198
- Anteris Data on File